File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients
  • Basic View
  • Metadata View
  • XML View
TitleEZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients
 
AuthorsRao, ZY1
Cai, MY1
Yang, GF1
He, LR1
Mai, SJ1
Hua, WF1
Liao, YJ1
Deng, HX1
Chen, YC2
Guan, XY1
Zeng, YX1
Kung, HF1 2
Xie, D1
 
Issue Date2010
 
PublisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/
 
CitationCarcinogenesis, 2010, v. 31 n. 9, p. 1576-1583 [How to Cite?]
DOI: http://dx.doi.org/10.1093/carcin/bgq150
 
AbstractIt was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. In this study, EZH2 expression was examined by immunohistochemistry (IHC) in cohorts of normal and tumorous ovarian tissues. High expression of EZH2 was examined in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors and in 50% of the ovarian carcinomas, respectively. In the ovarian carcinomas, high expression of EZH2 was positively correlated with an ascending histological grade and/or advanced stage of the disease (P < 0.05). Moreover, high expression of EZH2 in ovarian carcinoma was determined to be a strong and an independent predictor of short overall survival (P < 0.05). In ovarian carcinoma HO-8910 and UACC-326 cell lines, EZH2 knockdown by RNA interference led to a G 1 phase cell cycle arrest, reduced cell growth/proliferation and inhibited cell migration and/or invasion in vitro. In addition, EZH2 knockdown was found to reduce transforming growth factor-β1 (TGF-β1) expression and increase E-cadherin expression either in the transcript or in the protein levels. Furthermore, a significant positive correlation between overexpression of EZH2 and TGF-β1 in ovarian carcinoma tissues was observed (P < 0.001). These findings suggest a potential important role of EZH2 in the control of cell migration and/or invasion via the regulation of TGF-β1 expression, and the high expression of EZH2, as detected by IHC, is an independent molecular marker for shortened survival time of patients with ovarian carcinoma. © The Author 2010. Published by Oxford University Press. All rights reserved.
 
ISSN0143-3334
2013 Impact Factor: 5.266
 
DOIhttp://dx.doi.org/10.1093/carcin/bgq150
 
ISI Accession Number IDWOS:000281530400010
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
2010CB529401
Nature Science Foundation of China30772334
Funding Information:

Major State Basic Research Program of China (2006CB910104 and 2010CB529401); Nature Science Foundation of China (30772334).

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorRao, ZY
 
dc.contributor.authorCai, MY
 
dc.contributor.authorYang, GF
 
dc.contributor.authorHe, LR
 
dc.contributor.authorMai, SJ
 
dc.contributor.authorHua, WF
 
dc.contributor.authorLiao, YJ
 
dc.contributor.authorDeng, HX
 
dc.contributor.authorChen, YC
 
dc.contributor.authorGuan, XY
 
dc.contributor.authorZeng, YX
 
dc.contributor.authorKung, HF
 
dc.contributor.authorXie, D
 
dc.date.accessioned2012-06-26T06:11:40Z
 
dc.date.available2012-06-26T06:11:40Z
 
dc.date.issued2010
 
dc.description.abstractIt was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. In this study, EZH2 expression was examined by immunohistochemistry (IHC) in cohorts of normal and tumorous ovarian tissues. High expression of EZH2 was examined in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors and in 50% of the ovarian carcinomas, respectively. In the ovarian carcinomas, high expression of EZH2 was positively correlated with an ascending histological grade and/or advanced stage of the disease (P < 0.05). Moreover, high expression of EZH2 in ovarian carcinoma was determined to be a strong and an independent predictor of short overall survival (P < 0.05). In ovarian carcinoma HO-8910 and UACC-326 cell lines, EZH2 knockdown by RNA interference led to a G 1 phase cell cycle arrest, reduced cell growth/proliferation and inhibited cell migration and/or invasion in vitro. In addition, EZH2 knockdown was found to reduce transforming growth factor-β1 (TGF-β1) expression and increase E-cadherin expression either in the transcript or in the protein levels. Furthermore, a significant positive correlation between overexpression of EZH2 and TGF-β1 in ovarian carcinoma tissues was observed (P < 0.001). These findings suggest a potential important role of EZH2 in the control of cell migration and/or invasion via the regulation of TGF-β1 expression, and the high expression of EZH2, as detected by IHC, is an independent molecular marker for shortened survival time of patients with ovarian carcinoma. © The Author 2010. Published by Oxford University Press. All rights reserved.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationCarcinogenesis, 2010, v. 31 n. 9, p. 1576-1583 [How to Cite?]
DOI: http://dx.doi.org/10.1093/carcin/bgq150
 
dc.identifier.citeulike7842375
 
dc.identifier.doihttp://dx.doi.org/10.1093/carcin/bgq150
 
dc.identifier.epage1583
 
dc.identifier.isiWOS:000281530400010
Funding AgencyGrant Number
Major State Basic Research Program of China2006CB910104
2010CB529401
Nature Science Foundation of China30772334
Funding Information:

Major State Basic Research Program of China (2006CB910104 and 2010CB529401); Nature Science Foundation of China (30772334).

 
dc.identifier.issn0143-3334
2013 Impact Factor: 5.266
 
dc.identifier.issue9
 
dc.identifier.pmid20668008
 
dc.identifier.scopuseid_2-s2.0-77956277833
 
dc.identifier.spage1576
 
dc.identifier.urihttp://hdl.handle.net/10722/150831
 
dc.identifier.volume31
 
dc.languageeng
 
dc.publisherOxford University Press. The Journal's web site is located at http://carcin.oxfordjournals.org/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofCarcinogenesis
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAdenocarcinoma, Mucinous - Genetics - Metabolism - Pathology
 
dc.subject.meshAdolescent
 
dc.subject.meshAdult
 
dc.subject.meshAged
 
dc.subject.meshAged, 80 And Over
 
dc.subject.meshBlotting, Western
 
dc.subject.meshCell Adhesion
 
dc.subject.meshCell Cycle
 
dc.subject.meshCell Movement
 
dc.subject.meshCystadenocarcinoma, Serous - Genetics - Metabolism - Pathology
 
dc.subject.meshDna-Binding Proteins - Physiology
 
dc.subject.meshFemale
 
dc.subject.meshGene Expression Regulation, Neoplastic
 
dc.subject.meshHumans
 
dc.subject.meshImmunoenzyme Techniques
 
dc.subject.meshIn Situ Hybridization, Fluorescence
 
dc.subject.meshMiddle Aged
 
dc.subject.meshNeoplasm Invasiveness
 
dc.subject.meshNeoplasm Metastasis
 
dc.subject.meshNeoplasm Staging
 
dc.subject.meshOvarian Neoplasms - Genetics - Metabolism - Pathology
 
dc.subject.meshRna, Messenger - Genetics
 
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
 
dc.subject.meshSurvival Rate
 
dc.subject.meshTissue Array Analysis
 
dc.subject.meshTranscription Factors - Physiology
 
dc.subject.meshTransforming Growth Factor Beta1 - Genetics - Metabolism
 
dc.subject.meshTumor Cells, Cultured
 
dc.subject.meshYoung Adult
 
dc.titleEZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β 1 and is a predictor of outcome in ovarian carcinoma patients
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Rao, ZY</contributor.author>
<contributor.author>Cai, MY</contributor.author>
<contributor.author>Yang, GF</contributor.author>
<contributor.author>He, LR</contributor.author>
<contributor.author>Mai, SJ</contributor.author>
<contributor.author>Hua, WF</contributor.author>
<contributor.author>Liao, YJ</contributor.author>
<contributor.author>Deng, HX</contributor.author>
<contributor.author>Chen, YC</contributor.author>
<contributor.author>Guan, XY</contributor.author>
<contributor.author>Zeng, YX</contributor.author>
<contributor.author>Kung, HF</contributor.author>
<contributor.author>Xie, D</contributor.author>
<date.accessioned>2012-06-26T06:11:40Z</date.accessioned>
<date.available>2012-06-26T06:11:40Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Carcinogenesis, 2010, v. 31 n. 9, p. 1576-1583</identifier.citation>
<identifier.issn>0143-3334</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/150831</identifier.uri>
<description.abstract>It was suggested that the enhancer of zeste homolog 2 (EZH2) gene is a putative candidate oncogene in several types of human cancer. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in ovarian carcinoma are unclear. In this study, EZH2 expression was examined by immunohistochemistry (IHC) in cohorts of normal and tumorous ovarian tissues. High expression of EZH2 was examined in none of the normal ovaries, in 3% of the cystadenomas, in 23% of the borderline tumors and in 50% of the ovarian carcinomas, respectively. In the ovarian carcinomas, high expression of EZH2 was positively correlated with an ascending histological grade and/or advanced stage of the disease (P &lt; 0.05). Moreover, high expression of EZH2 in ovarian carcinoma was determined to be a strong and an independent predictor of short overall survival (P &lt; 0.05). In ovarian carcinoma HO-8910 and UACC-326 cell lines, EZH2 knockdown by RNA interference led to a G 1 phase cell cycle arrest, reduced cell growth/proliferation and inhibited cell migration and/or invasion in vitro. In addition, EZH2 knockdown was found to reduce transforming growth factor-&#946;1 (TGF-&#946;1) expression and increase E-cadherin expression either in the transcript or in the protein levels. Furthermore, a significant positive correlation between overexpression of EZH2 and TGF-&#946;1 in ovarian carcinoma tissues was observed (P &lt; 0.001). These findings suggest a potential important role of EZH2 in the control of cell migration and/or invasion via the regulation of TGF-&#946;1 expression, and the high expression of EZH2, as detected by IHC, is an independent molecular marker for shortened survival time of patients with ovarian carcinoma. &#169; The Author 2010. Published by Oxford University Press. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Oxford University Press. The Journal&apos;s web site is located at http://carcin.oxfordjournals.org/</publisher>
<relation.ispartof>Carcinogenesis</relation.ispartof>
<subject.mesh>Adenocarcinoma, Mucinous - Genetics - Metabolism - Pathology</subject.mesh>
<subject.mesh>Adolescent</subject.mesh>
<subject.mesh>Adult</subject.mesh>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Aged, 80 And Over</subject.mesh>
<subject.mesh>Blotting, Western</subject.mesh>
<subject.mesh>Cell Adhesion</subject.mesh>
<subject.mesh>Cell Cycle</subject.mesh>
<subject.mesh>Cell Movement</subject.mesh>
<subject.mesh>Cystadenocarcinoma, Serous - Genetics - Metabolism - Pathology</subject.mesh>
<subject.mesh>Dna-Binding Proteins - Physiology</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Gene Expression Regulation, Neoplastic</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Immunoenzyme Techniques</subject.mesh>
<subject.mesh>In Situ Hybridization, Fluorescence</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Neoplasm Invasiveness</subject.mesh>
<subject.mesh>Neoplasm Metastasis</subject.mesh>
<subject.mesh>Neoplasm Staging</subject.mesh>
<subject.mesh>Ovarian Neoplasms - Genetics - Metabolism - Pathology</subject.mesh>
<subject.mesh>Rna, Messenger - Genetics</subject.mesh>
<subject.mesh>Reverse Transcriptase Polymerase Chain Reaction</subject.mesh>
<subject.mesh>Survival Rate</subject.mesh>
<subject.mesh>Tissue Array Analysis</subject.mesh>
<subject.mesh>Transcription Factors - Physiology</subject.mesh>
<subject.mesh>Transforming Growth Factor Beta1 - Genetics - Metabolism</subject.mesh>
<subject.mesh>Tumor Cells, Cultured</subject.mesh>
<subject.mesh>Young Adult</subject.mesh>
<title>EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-&#946; 1 and is a predictor of outcome in ovarian carcinoma patients</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1093/carcin/bgq150</identifier.doi>
<identifier.pmid>20668008</identifier.pmid>
<identifier.scopus>eid_2-s2.0-77956277833</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77956277833&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>31</identifier.volume>
<identifier.issue>9</identifier.issue>
<identifier.spage>1576</identifier.spage>
<identifier.epage>1583</identifier.epage>
<identifier.isi>WOS:000281530400010</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>7842375</identifier.citeulike>
</item>
Author Affiliations
  1. Sun Yat-Sen University
  2. Chinese University of Hong Kong